サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1791625

樹状細胞がんワクチンの世界市場

Dendritic Cell Cancer Vaccines

出版日
ページ情報
英文 142 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.53円
樹状細胞がんワクチンの世界市場
出版日: 2025年08月15日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 142 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

樹状細胞がんワクチンの世界市場は2030年までに17億米ドルに達する見込み

2024年に8億610万米ドルと推定される樹状細胞がんワクチンの世界市場は、2030年には17億米ドルに達し、分析期間2024-2030年のCAGRは13.0％で成長すると予測されます。本レポートで分析したセグメントの1つであるCipuleucel-T Vaccinesは、CAGR 14.7%を記録し、分析期間終了時には9億8,770万米ドルに達すると予測されます。CreaVaxワクチン分野の成長率は、分析期間中CAGR 12.0%と推定されます。

米国市場は2億1,190万米ドルと推定、中国はCAGR 12.1％で成長予測

米国の樹状細胞がんワクチン市場は、2024年に2億1,190万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを12.1%として、2030年までに2億5,960万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ12.2％と11.0％と予測されています。欧州では、ドイツがCAGR 9.3%で成長すると予測されています。

世界の樹状細胞がんワクチン市場- 主要動向と促進要因のまとめ

なぜ樹状細胞がんワクチンが免疫療法で注目されているのか？

樹状細胞（DC）がんワクチンは、悪性腫瘍と闘うために身体の免疫システムを活用する、がん治療における有望なフロンティアとして浮上してきました。重篤な副作用を伴うことが多い化学療法や放射線療法といった従来のがん治療とは異なり、樹状細胞ワクチンは、がん治療に個別化された標的アプローチを提供します。これらのワクチンは、樹状細胞を腫瘍抗原でプライミングし、がん細胞に対する免疫反応を高めるためにT細胞を活性化させることで機能します。免疫療法が実行可能ながん治療法として認識されるようになったことで、樹状細胞をベースとしたワクチンの研究と投資が推進されています。メラノーマ、前立腺がん、肺がん、膠芽腫などのがんの罹患率の増加が、個別化ワクチン戦略への関心をさらに高めています。さらに、がんゲノム学や分子生物学における画期的な進歩により、ワクチンの有効性が向上し、攻撃的で治療抵抗性のがん患者に新たな希望がもたらされています。研究が進むにつれて、DCワクチンはチェックポイント阻害剤やCAR-T細胞療法などの既存の免疫療法を補完する可能性が評価され、より包括的で耐久性のあるがん治療の展望が生まれつつあります。

バイオテクノロジーの進歩はDCワクチン開発をどのように促進しているのか？

樹状細胞がんワクチンの開発は、遺伝子編集、合成生物学、ナノテクノロジーなどのバイオテクノロジーの進歩によって著しく強化されています。CRISPRに基づく遺伝子編集により、研究者は抗原提示能力を強化した樹状細胞を工学的に作製することが可能となり、免疫系を刺激する有効性が向上しました。さらに、COVID-19ワクチンで普及したメッセンジャーRNA（mRNA）技術の使用は、腫瘍抗原をより効率的に搭載した次世代樹状細胞ワクチン開発のために研究されています。ナノキャリアや脂質ナノ粒子の技術革新もワクチン送達を改善し、治療用樹状細胞の生物学的利用能と安定性を高めています。さらに、人工知能（AI）とビッグデータ解析は、新規がん抗原を同定し、異なる腫瘍タイプに対する樹状細胞ワクチンの個別化を最適化するために採用されています。このような技術的進歩が進化を続けるにつれて、より効果的でスケーラブルな樹状細胞がんワクチンプラットフォームの開発が促進されると期待されます。

樹状細胞ワクチンが直面する規制と市場の課題とは？

その可能性にもかかわらず、樹状細胞がんワクチンはいくつかの規制上および商業上の課題に直面しています。各ワクチンは個々の患者の腫瘍プロファイルに合わせる必要があるため、個別化ワクチン製造の高コストと複雑さは依然として大きなハードルとなっています。さらに、細胞免疫療法の厳しい承認プロセスには、大規模な臨床試験と長期的な有効性データが必要であり、市場参入を遅らせています。樹状細胞の調製と抗原負荷のための標準化されたプロトコールがないことも、異なる患者グループ間でのワクチン効果のばらつきにつながっています。しかし、FDAやEMAなどの規制機関は免疫療法研究を支援する動きを強めており、有望な樹状細胞ワクチン候補に対してファスト・トラック指定を行っています。さらに、バイオテクノロジー企業と研究機関は戦略的パートナーシップを結び、生産規模の拡大とコスト削減を図っています。自動化技術やバイオプロセス技術への継続的な投資により、DCワクチンの商業化を取り巻く課題は徐々に緩和されていくと予想されます。

樹状細胞がんワクチン市場の主な成長促進要因は？

樹状細胞がんワクチン市場の成長は、世界のがん罹患率の上昇や個別化免疫療法ソリューションに対する需要の増加など、いくつかの要因によってもたらされます。バイオテクノロジー、特に遺伝子編集、mRNA技術、ナノメディシンの進歩により、DCワクチンの有効性と拡張性が大幅に向上しています。樹状細胞ワクチンとチェックポイント阻害剤やモノクローナル抗体を組み合わせた併用免疫療法の採用が拡大しており、治療の可能性がさらに広がっています。迅速承認パスウェイを含む細胞性免疫療法に対する規制当局の支援により、新規DCワクチン候補の臨床試験と市場参入が加速しています。さらに、政府機関、研究機関、バイオテクノロジー企業からの資金提供の増加が、技術革新と商業化の努力を後押ししています。がん免疫療法の分野が進化を続ける中、樹状細胞がんワクチンは、治療が困難ながん患者を対象とした持続的な解決策を提供し、将来の腫瘍学において重要な役割を果たすと期待されています。

セグメント

製品（Sipuleucel-T Vaccines, CreaVax Vaccines, Other Products）;エンドユーザー（Adults Vaccines End-Use, Pediatrics Vaccines End-Use）

調査対象企業の例

  • Argos Therapeutics, Inc.
  • Asgard Therapeutics
  • BioNTech SE
  • Candel Therapeutics
  • CureVac N.V.
  • Dendreon Pharmaceuticals LLC
  • Diakonos Oncology
  • Genexine, Inc.
  • GlaxoSmithKline plc（GSK）
  • ImmunoCellular Therapeutics, Ltd.
  • Immunomic Therapeutics, Inc.
  • Medigene AG
  • Mestag Therapeutics
  • Mill Creek Life Sciences
  • Moderna, Inc.
  • Northwest Biotherapeutics
  • PDC*line Pharma
  • Scancell Holdings plc
  • SOTIO Biotech
  • TransImmune AG

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界固有のSLMをクエリする代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP30414

Global Dendritic Cell Cancer Vaccines Market to Reach US$1.7 Billion by 2030

The global market for Dendritic Cell Cancer Vaccines estimated at US$806.1 Million in the year 2024, is expected to reach US$1.7 Billion by 2030, growing at a CAGR of 13.0% over the analysis period 2024-2030. Sipuleucel-T Vaccines, one of the segments analyzed in the report, is expected to record a 14.7% CAGR and reach US$987.7 Million by the end of the analysis period. Growth in the CreaVax Vaccines segment is estimated at 12.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$211.9 Million While China is Forecast to Grow at 12.1% CAGR

The Dendritic Cell Cancer Vaccines market in the U.S. is estimated at US$211.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$259.6 Million by the year 2030 trailing a CAGR of 12.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.2% and 11.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.3% CAGR.

Global Dendritic Cell Cancer Vaccines Market - Key Trends & Drivers Summarized

Why Are Dendritic Cell Cancer Vaccines Gaining Attention in Immunotherapy?

Dendritic cell (DC) cancer vaccines have emerged as a promising frontier in oncology, leveraging the body’s immune system to combat malignancies. Unlike traditional cancer treatments such as chemotherapy and radiation, which often have severe side effects, DC vaccines offer a personalized and targeted approach to cancer therapy. These vaccines work by priming dendritic cells with tumor antigens, enabling them to activate T-cells for an enhanced immune response against cancer cells. The growing recognition of immunotherapy as a viable cancer treatment has propelled research and investment in dendritic cell-based vaccines. The increasing incidence of cancers such as melanoma, prostate, lung, and glioblastoma has further fueled interest in personalized vaccine strategies. Additionally, breakthroughs in cancer genomics and molecular biology are improving vaccine efficacy, offering new hope for patients with aggressive and treatment-resistant cancers. As research progresses, DC vaccines are being evaluated for their potential to complement existing immunotherapies, such as checkpoint inhibitors and CAR-T cell therapy, creating a more comprehensive and durable cancer treatment landscape.

How Are Advancements in Biotechnology Enhancing DC Vaccine Development?

The development of dendritic cell cancer vaccines has been significantly enhanced by advancements in biotechnology, including gene editing, synthetic biology, and nanotechnology. CRISPR-based gene editing has enabled researchers to engineer dendritic cells with enhanced antigen presentation capabilities, improving their effectiveness in stimulating the immune system. Additionally, the use of messenger RNA (mRNA) technology-popularized by COVID-19 vaccines-is being explored for developing next-generation DC vaccines with more efficient tumor antigen loading. Innovations in nanocarriers and lipid nanoparticles have also improved vaccine delivery, enhancing the bioavailability and stability of therapeutic dendritic cells. Furthermore, artificial intelligence (AI) and big data analytics are being employed to identify novel cancer antigens, optimizing the personalization of DC vaccines for different tumor types. As these technological advancements continue to evolve, they are expected to drive the development of more effective and scalable dendritic cell cancer vaccine platforms.

What Are the Regulatory and Market Challenges Facing DC Vaccines?

Despite their potential, dendritic cell cancer vaccines face several regulatory and commercial challenges. The high cost and complexity of personalized vaccine manufacturing remain significant hurdles, as each vaccine must be tailored to an individual patient’s tumor profile. Additionally, the stringent regulatory approval process for cellular immunotherapies requires extensive clinical trials and long-term efficacy data, delaying market entry. The lack of standardized protocols for dendritic cell preparation and antigen loading has also led to variability in vaccine effectiveness across different patient groups. However, regulatory agencies such as the FDA and EMA are increasingly supporting immunotherapy research, providing fast-track designations for promising DC vaccine candidates. Additionally, biotech companies and research institutions are forming strategic partnerships to scale up production and reduce costs. With continued investment in automation and bioprocessing technologies, the challenges surrounding DC vaccine commercialization are expected to be gradually mitigated.

What Are the Key Growth Drivers in the Dendritic Cell Cancer Vaccines Market?

The growth in the dendritic cell cancer vaccines market is driven by several factors, including the rising global cancer burden and increasing demand for personalized immunotherapy solutions. Advances in biotechnology, particularly in gene editing, mRNA technology, and nanomedicine, have significantly enhanced the efficacy and scalability of DC vaccines. The growing adoption of combination immunotherapies, integrating DC vaccines with checkpoint inhibitors and monoclonal antibodies, has further expanded treatment possibilities. Regulatory support for cellular immunotherapies, including expedited approval pathways, has accelerated clinical trials and market entry for new DC vaccine candidates. Additionally, increased funding from government agencies, research institutions, and biotech firms has driven innovation and commercialization efforts. As the field of cancer immunotherapy continues to evolve, dendritic cell cancer vaccines are expected to play a critical role in the future of oncology, offering a targeted and durable solution for patients with hard-to-treat cancers.

SCOPE OF STUDY:

The report analyzes the Dendritic Cell Cancer Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Sipuleucel-T Vaccines, CreaVax Vaccines, Other Products); End-Use (Adults Vaccines End-Use, Pediatrics Vaccines End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 44 Featured) -

  • Argos Therapeutics, Inc.
  • Asgard Therapeutics
  • BioNTech SE
  • Candel Therapeutics
  • CureVac N.V.
  • Dendreon Pharmaceuticals LLC
  • Diakonos Oncology
  • Genexine, Inc.
  • GlaxoSmithKline plc (GSK)
  • ImmunoCellular Therapeutics, Ltd.
  • Immunomic Therapeutics, Inc.
  • Medigene AG
  • Mestag Therapeutics
  • Mill Creek Life Sciences
  • Moderna, Inc.
  • Northwest Biotherapeutics
  • PDC*line Pharma
  • Scancell Holdings plc
  • SOTIO Biotech
  • TransImmune AG

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Dendritic Cell Cancer Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advances in Immuno-Oncology Throw the Spotlight on Dendritic Cell Cancer Vaccines as a Personalized Therapy Frontier
    • Rising Global Cancer Burden Spurs Interest in Novel, Targeted Treatment Modalities
    • Breakthroughs in Antigen Presentation and T-Cell Activation Strengthen the Case for Dendritic Cell Therapies
    • Clinical Trial Momentum and Pipeline Expansion Accelerate Innovation in DC Vaccine Platforms
    • Favorable Regulatory Pathways for Cell-Based Immunotherapies Support Fast-Track Approvals
    • Increased Collaboration Between Academia and Biotech Fuels R&D in Personalized Cancer Vaccines
    • Integration of Genomic and Neoantigen Profiling Enhances Precision in Dendritic Cell Vaccine Design
    • Growing Acceptance of Autologous and Allogeneic Cell Therapies Expands Use in Solid Tumors and Hematologic Cancers
    • Combination Therapies with Checkpoint Inhibitors Drive Synergistic Treatment Strategies
    • Cryopreservation and Manufacturing Advances Improve Scalability and Patient Access
    • Reimbursement Progress and Orphan Drug Incentives Encourage Market Entry for Niche Indications
    • Patient Demand for Personalized Medicine Drives Interest in Tumor-Antigen-Targeted DC Vaccines
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Dendritic Cell Cancer Vaccines Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Dendritic Cell Cancer Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Sipuleucel-T Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Sipuleucel-T Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for CreaVax Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for CreaVax Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Adults Vaccines End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Adults Vaccines End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Pediatrics Vaccines End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Pediatrics Vaccines End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Dendritic Cell Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by Product - Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 15: USA 6-Year Perspective for Dendritic Cell Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products for the Years 2025 & 2030
    • TABLE 16: USA Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by End-Use - Adults Vaccines End-Use and Pediatrics Vaccines End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 17: USA 6-Year Perspective for Dendritic Cell Cancer Vaccines by End-Use - Percentage Breakdown of Value Sales for Adults Vaccines End-Use and Pediatrics Vaccines End-Use for the Years 2025 & 2030
  • CANADA
    • TABLE 18: Canada Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by Product - Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 19: Canada 6-Year Perspective for Dendritic Cell Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products for the Years 2025 & 2030
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by End-Use - Adults Vaccines End-Use and Pediatrics Vaccines End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: Canada 6-Year Perspective for Dendritic Cell Cancer Vaccines by End-Use - Percentage Breakdown of Value Sales for Adults Vaccines End-Use and Pediatrics Vaccines End-Use for the Years 2025 & 2030
  • JAPAN
    • Dendritic Cell Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 22: Japan Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by Product - Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 23: Japan 6-Year Perspective for Dendritic Cell Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products for the Years 2025 & 2030
    • TABLE 24: Japan Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by End-Use - Adults Vaccines End-Use and Pediatrics Vaccines End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 25: Japan 6-Year Perspective for Dendritic Cell Cancer Vaccines by End-Use - Percentage Breakdown of Value Sales for Adults Vaccines End-Use and Pediatrics Vaccines End-Use for the Years 2025 & 2030
  • CHINA
    • Dendritic Cell Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 26: China Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by Product - Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: China 6-Year Perspective for Dendritic Cell Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products for the Years 2025 & 2030
    • TABLE 28: China Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by End-Use - Adults Vaccines End-Use and Pediatrics Vaccines End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: China 6-Year Perspective for Dendritic Cell Cancer Vaccines by End-Use - Percentage Breakdown of Value Sales for Adults Vaccines End-Use and Pediatrics Vaccines End-Use for the Years 2025 & 2030
  • EUROPE
    • Dendritic Cell Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 30: Europe Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 31: Europe 6-Year Perspective for Dendritic Cell Cancer Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by Product - Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Europe 6-Year Perspective for Dendritic Cell Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products for the Years 2025 & 2030
    • TABLE 34: Europe Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by End-Use - Adults Vaccines End-Use and Pediatrics Vaccines End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Europe 6-Year Perspective for Dendritic Cell Cancer Vaccines by End-Use - Percentage Breakdown of Value Sales for Adults Vaccines End-Use and Pediatrics Vaccines End-Use for the Years 2025 & 2030
  • FRANCE
    • Dendritic Cell Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 36: France Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by Product - Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: France 6-Year Perspective for Dendritic Cell Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products for the Years 2025 & 2030
    • TABLE 38: France Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by End-Use - Adults Vaccines End-Use and Pediatrics Vaccines End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: France 6-Year Perspective for Dendritic Cell Cancer Vaccines by End-Use - Percentage Breakdown of Value Sales for Adults Vaccines End-Use and Pediatrics Vaccines End-Use for the Years 2025 & 2030
  • GERMANY
    • Dendritic Cell Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 40: Germany Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by Product - Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Germany 6-Year Perspective for Dendritic Cell Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products for the Years 2025 & 2030
    • TABLE 42: Germany Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by End-Use - Adults Vaccines End-Use and Pediatrics Vaccines End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Germany 6-Year Perspective for Dendritic Cell Cancer Vaccines by End-Use - Percentage Breakdown of Value Sales for Adults Vaccines End-Use and Pediatrics Vaccines End-Use for the Years 2025 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by Product - Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Italy 6-Year Perspective for Dendritic Cell Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products for the Years 2025 & 2030
    • TABLE 46: Italy Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by End-Use - Adults Vaccines End-Use and Pediatrics Vaccines End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Italy 6-Year Perspective for Dendritic Cell Cancer Vaccines by End-Use - Percentage Breakdown of Value Sales for Adults Vaccines End-Use and Pediatrics Vaccines End-Use for the Years 2025 & 2030
  • UNITED KINGDOM
    • Dendritic Cell Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 48: UK Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by Product - Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: UK 6-Year Perspective for Dendritic Cell Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products for the Years 2025 & 2030
    • TABLE 50: UK Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by End-Use - Adults Vaccines End-Use and Pediatrics Vaccines End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: UK 6-Year Perspective for Dendritic Cell Cancer Vaccines by End-Use - Percentage Breakdown of Value Sales for Adults Vaccines End-Use and Pediatrics Vaccines End-Use for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 52: Rest of Europe Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by Product - Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Rest of Europe 6-Year Perspective for Dendritic Cell Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products for the Years 2025 & 2030
    • TABLE 54: Rest of Europe Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by End-Use - Adults Vaccines End-Use and Pediatrics Vaccines End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Rest of Europe 6-Year Perspective for Dendritic Cell Cancer Vaccines by End-Use - Percentage Breakdown of Value Sales for Adults Vaccines End-Use and Pediatrics Vaccines End-Use for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Dendritic Cell Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by Product - Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific 6-Year Perspective for Dendritic Cell Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products for the Years 2025 & 2030
    • TABLE 58: Asia-Pacific Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by End-Use - Adults Vaccines End-Use and Pediatrics Vaccines End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Asia-Pacific 6-Year Perspective for Dendritic Cell Cancer Vaccines by End-Use - Percentage Breakdown of Value Sales for Adults Vaccines End-Use and Pediatrics Vaccines End-Use for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 60: Rest of World Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by Product - Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Rest of World 6-Year Perspective for Dendritic Cell Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Sipuleucel-T Vaccines, CreaVax Vaccines and Other Products for the Years 2025 & 2030
    • TABLE 62: Rest of World Recent Past, Current & Future Analysis for Dendritic Cell Cancer Vaccines by End-Use - Adults Vaccines End-Use and Pediatrics Vaccines End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Rest of World 6-Year Perspective for Dendritic Cell Cancer Vaccines by End-Use - Percentage Breakdown of Value Sales for Adults Vaccines End-Use and Pediatrics Vaccines End-Use for the Years 2025 & 2030

IV. COMPETITION